{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:42:23Z","timestamp":1793644943561,"version":"4.5.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"vor","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.immuni.2021.03.009","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T05:53:02Z","timestamp":1618465982000},"page":"815-828.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus"],"prefix":"10.1016","volume":"54","author":[{"given":"Bronwyn M.","family":"Gunn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8288-787X","authenticated-orcid":false,"given":"Matthew D.","family":"Slein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp A.","family":"Ilinykh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3373-5594","authenticated-orcid":false,"given":"Kai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7489-0232","authenticated-orcid":false,"given":"Caroline","family":"Atyeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-7261","authenticated-orcid":false,"given":"Sharon L.","family":"Schendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4141-275X","authenticated-orcid":false,"given":"Caitlin","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9811-9792","authenticated-orcid":false,"given":"Todd J.","family":"Suscovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayato","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Halfmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9212-4307","authenticated-orcid":false,"given":"Matthias G.","family":"Pauthner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mambu","family":"Momoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine","family":"Goba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lansana","family":"Kanneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian G.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Schieffelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Garry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-7451","authenticated-orcid":false,"given":"Erica Ollmann","family":"Saphire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0342-4824","authenticated-orcid":false,"given":"Alexander","family":"Bukreyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galit","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2021.03.009_bib1","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/s41591-018-0161-0","article-title":"Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV","volume":"24","author":"Ackerman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2021.03.009_bib2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/infdis\/jit609","article-title":"Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses","volume":"209","author":"Agnihothram","year":"2014","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.03.009_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-pathol-052016-100506","article-title":"The Pathogenesis of Ebola Virus Disease","volume":"12","author":"Baseler","year":"2017","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.immuni.2021.03.009_bib4","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1126\/science.aad5788","article-title":"Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak","volume":"351","author":"Bornholdt","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.03.009_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.chom.2018.12.005","article-title":"A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates","volume":"25","author":"Bornholdt","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2021.03.009_bib6","doi-asserted-by":"crossref","first-page":"20054","DOI":"10.1073\/pnas.1911842116","article-title":"Differential requirements for Fc\u03b3R engagement by protective antibodies against Ebola virus","volume":"116","author":"Bournazos","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.03.009_bib7","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1086\/515386","article-title":"A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever","volume":"178","author":"Bray","year":"1998","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.03.009_bib8","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2021.03.009_bib9","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1016\/j.molimm.2008.06.027","article-title":"Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies","volume":"45","author":"Chu","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.immuni.2021.03.009_bib10","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1073\/pnas.1510199112","article-title":"Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus","volume":"112","author":"Corti","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.03.009_bib11","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.03.009_bib12","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.4049\/jimmunol.169.9.5171","article-title":"Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences","volume":"169","author":"Dall\u2019Acqua","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2021.03.009_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1124\/dmd.106.011734","article-title":"Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates","volume":"35","author":"Datta-Mannan","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.immuni.2021.03.009_bib14","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.03.009_bib15","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","article-title":"Affinity of human IgG subclasses to mouse Fc gamma receptors","volume":"9","author":"Dekkers","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/j.immuni.2021.03.009_bib16","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1371\/journal.pmed.0030525","article-title":"Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants","volume":"3","author":"Deming","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.immuni.2021.03.009_bib17","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.03.009_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc\u03b3R interactions for protection against influenza virus in\u00a0vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2021.03.009_bib19","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1371\/journal.pone.0003647","article-title":"A one pot, one step, precision cloning method with high throughput capability","volume":"3","author":"Engler","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.immuni.2021.03.009_bib20","doi-asserted-by":"crossref","first-page":"112630","DOI":"10.1016\/j.jim.2019.07.002","article-title":"A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation","volume":"473","author":"Fischinger","year":"2019","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.immuni.2021.03.009_bib21","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cell.2015.12.022","article-title":"Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection","volume":"164","author":"Flyak","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2021.03.009_bib22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.immuni.2018.06.018","article-title":"Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein","volume":"49","author":"Gilchuk","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2021.03.009_bib23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.chom.2018.07.009","article-title":"A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus","volume":"24","author":"Gunn","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2021.03.009_bib24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/infdis\/jiz364","article-title":"Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses","volume":"221","author":"Gunn","year":"2020","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.03.009_bib25","doi-asserted-by":"crossref","first-page":"11931","DOI":"10.1073\/pnas.1609316113","article-title":"Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus","volume":"113","author":"He","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.03.009_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2021.03.009_bib27","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1074\/jbc.C300470200","article-title":"Engineered human IgG antibodies with longer serum half-lives in primates","volume":"279","author":"Hinton","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.immuni.2021.03.009_bib28","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.4049\/jimmunol.164.8.4178","article-title":"Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc","volume":"164","author":"Idusogie","year":"2000","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2021.03.009_bib29","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.4049\/jimmunol.166.4.2571","article-title":"Engineered antibodies with increased activity to recruit complement","volume":"166","author":"Idusogie","year":"2001","journal-title":"J.\u00a0Immunol."},{"issue":"suppl_5","key":"10.1016\/j.immuni.2021.03.009_bib30","first-page":"S418","article-title":"Ebolavirus Chimerization for the Development of a Mouse Model for Screening of Bundibugyo-Specific Antibodies","volume":"218","author":"Ilinykh","year":"2018","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.immuni.2021.03.009_bib31","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.chom.2020.03.025","article-title":"Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies","volume":"27","author":"Ilinykh","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2021.03.009_bib32","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1128\/JVI.00671-11","article-title":"Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent Fc\u03b3R pathway","volume":"85","author":"Jaume","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.03.009_bib33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2021.03.009_bib34","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1089\/0889222041524571","article-title":"Characterization of molecular features, antigen-binding, and in\u00a0vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody","volume":"20","author":"Kunert","year":"2004","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.immuni.2021.03.009_bib35","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1073\/pnas.0508123103","article-title":"Engineered antibody Fc variants with enhanced effector function","volume":"103","author":"Lazar","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.03.009_bib36","doi-asserted-by":"crossref","first-page":"123158","DOI":"10.1172\/jci.insight.123158","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.immuni.2021.03.009_bib37","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.03.009_bib38","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.aad6117","article-title":"Structural and molecular basis for Ebola virus neutralization by protective human antibodies","volume":"351","author":"Misasi","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.03.009_bib39","doi-asserted-by":"crossref","first-page":"10572","DOI":"10.1128\/JVI.05541-11","article-title":"A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fc\u03b3 receptors to define the role of effector functions in protection against HIV","volume":"85","author":"Moldt","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.03.009_bib40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4161\/mabs.2.2.11158","article-title":"Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions","volume":"2","author":"Moore","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.immuni.2021.03.009_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.immuni.2005.05.010","article-title":"FcgammaRIV: a novel FcR with distinct IgG subclass specificity","volume":"23","author":"Nimmerjahn","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2021.03.009_bib42","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00251-006-0142-1","article-title":"Genomic view of the evolution of the complement system","volume":"58","author":"Nonaka","year":"2006","journal-title":"Immunogenetics"},{"key":"10.1016\/j.immuni.2021.03.009_bib43","doi-asserted-by":"crossref","first-page":"18030","DOI":"10.1073\/pnas.1213709109","article-title":"Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques","volume":"109","author":"Olinger","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.03.009_bib44","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.4049\/jimmunol.1200356","article-title":"Crosstalk between human IgG isotypes and murine effector cells","volume":"189","author":"Overdijk","year":"2012","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2021.03.009_bib45","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.1128\/JVI.76.12.6408-6412.2002","article-title":"Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody","volume":"76","author":"Parren","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.03.009_bib46","article-title":"Structural and functional analysis of a potent sarbecovirus neutralizing antibody","author":"Pinto","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.immuni.2021.03.009_bib47","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1084\/jem.20020781","article-title":"A role for immune complexes in enhanced respiratory syncytial virus disease","volume":"196","author":"Polack","year":"2002","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2021.03.009_bib48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2021.03.009_bib49","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1158\/1535-7163.MCT-08-0201","article-title":"Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells","volume":"7","author":"Richards","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.immuni.2021.03.009_bib50","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection","volume":"174","author":"Saphire","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2021.03.009_bib51","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41590-018-0233-9","article-title":"Antibody-mediated protection against Ebola virus","volume":"19","author":"Saphire","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2021.03.009_bib52","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R","volume":"276","author":"Shields","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.immuni.2021.03.009_bib53","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1073\/pnas.1203954109","article-title":"Mouse model recapitulating human Fc\u03b3 receptor structural and functional diversity","volume":"109","author":"Smith","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.03.009_bib54","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.1158\/0008-5472.CAN-07-0696","article-title":"Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in\u00a0vitro and controls tumor expansion in\u00a0vivo via low-affinity activating Fcgamma receptors","volume":"67","author":"Stavenhagen","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.immuni.2021.03.009_bib55","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.4049\/jimmunol.155.3.1165","article-title":"Ex\u00a0vivo coating of islet cell allografts with murine CTLA4\/Fc promotes graft tolerance","volume":"155","author":"Steurer","year":"1995","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2021.03.009_bib56","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/s41598-018-36972-2","article-title":"NK Cells Activated through Antibody-Dependent Cell Cytotoxicity and Armed with Degranulation\/IFN-\u03b3 Production Suppress Antibody-dependent Enhancement of Dengue Viral Infection","volume":"9","author":"Sun","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.immuni.2021.03.009_bib57","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3389\/fimmu.2019.00548","article-title":"Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease","volume":"10","author":"van Erp","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2021.03.009_bib58","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nri.2017.148","article-title":"Passive immunotherapy of viral infections: \u2018super-antibodies\u2019 enter the fray","volume":"18","author":"Walker","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2021.03.009_bib59","doi-asserted-by":"crossref","first-page":"e02015-19","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry","volume":"94","author":"Wan","year":"2020","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.immuni.2021.03.009_bib60","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","article-title":"Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins","volume":"451","author":"Wang","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.immuni.2021.03.009_bib61","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1126\/science.aai8128","article-title":"IgG antibodies to dengue enhanced for Fc\u03b3RIIIA binding determine disease severity","volume":"355","author":"Wang","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.immuni.2021.03.009_bib62","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1084\/jem.20032141","article-title":"Role of natural killer cells in innate protection against lethal ebola virus infection","volume":"200","author":"Warfield","year":"2004","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2021.03.009_bib63","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cell.2017.04.037","article-title":"Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses","volume":"169","author":"Wec","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2021.03.009_bib64","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(09)60251-8","article-title":"Monoclonal antibodies for cancer immunotherapy","volume":"373","author":"Weiner","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.immuni.2021.03.009_bib65","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/cimm.2000.1617","article-title":"In\u00a0vitro characterization of five humanized OKT3 effector function variant antibodies","volume":"200","author":"Xu","year":"2000","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.immuni.2021.03.009_bib66","doi-asserted-by":"crossref","first-page":"7663","DOI":"10.4049\/jimmunol.0804182","article-title":"Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates","volume":"182","author":"Yeung","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2021.03.009_bib67","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in\u00a0vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.immuni.2021.03.009_bib68","doi-asserted-by":"crossref","first-page":"20690","DOI":"10.1073\/pnas.1108360108","article-title":"Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant","volume":"108","author":"Zeitlin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2021.03.009_bib69","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cell.2017.04.038","article-title":"Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability","volume":"169","author":"Zhao","year":"2017","journal-title":"Cell"}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761321001217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761321001217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:12:32Z","timestamp":1761034352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761321001217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1074761321001217"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2021.03.009","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2021.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}